Roche: Liberum downgrades 'buy' rating
(CercleFinance.com) - Liberum has downgraded its "buy" recommendation on the Roche share to "hold," with a target price of 275 Swiss francs, noting that over the last 12 months the consensus has raised its medium-term estimates by 9%-11%, while the stock has risen by 33%.
The broker now only sees limited room for further increases as it believes that announcements about the group's product pipeline are also less significant now, with it now no longer recommending investors buy the share.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The broker now only sees limited room for further increases as it believes that announcements about the group's product pipeline are also less significant now, with it now no longer recommending investors buy the share.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.